Vera’s Atacicept Passes Phase II IgAN Trial But Data Pale Beside Chinook’s Pipeline Rival
Pivotal Trial Plans Underway
The US biotech’s dual cytokine inhibitor has hit significance in a mid-stage trial with plans underway for a Phase III study, but concerns about its lacklustre efficacy when compared with a rival candidate from Chinook have taken the wind out of its sails.
